Stock Analysis

Nyrada (ASX:NYR) shareholder returns have been stellar, earning 185% in 3 years

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But in contrast you can make much more than 100% if the company does well. For example, the Nyrada Inc. (ASX:NYR) share price has soared 185% in the last three years. How nice for those who held the stock! And in the last month, the share price has gained 48%.

The past week has proven to be lucrative for Nyrada investors, so let's see if fundamentals drove the company's three-year performance.

Because Nyrada made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Nyrada's revenue trended up 16% each year over three years. That's a very respectable growth rate. Broadly speaking, this solid progress may well be reflected by the healthy share price gain of 42% per year over three years. The business has made good progress on the top line, but the market is extrapolating the growth. Some investors like to buy in just after a company becomes profitable, since that can be a powerful inflexion point.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
ASX:NYR Earnings and Revenue Growth October 15th 2025

We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. It might be well worthwhile taking a look at our free report on Nyrada's earnings, revenue and cash flow.

Advertisement

A Different Perspective

It's nice to see that Nyrada shareholders have received a total shareholder return of 174% over the last year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 12% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 3 warning signs we've spotted with Nyrada (including 1 which makes us a bit uncomfortable) .

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges.

Valuation is complex, but we're here to simplify it.

Discover if Nyrada might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ASX:NYR

Nyrada

A pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases.

Flawless balance sheet with very low risk.

Advertisement

Weekly Picks

FA
7202 logo
FAI on Arabian Internet and Communication Services ·

Solutions by stc: 34% Upside in Saudi's Digital Transformation Leader

Fair Value:ر.س342.2335.5% undervalued
10 users have followed this narrative
1 users have commented on this narrative
4 users have liked this narrative
RO
RobertoAllende
NVDA logo
RobertoAllende on NVIDIA ·

The AI Infrastructure Giant Grows Into Its Valuation

Fair Value:US$345.0747.9% undervalued
28 users have followed this narrative
28 users have commented on this narrative
21 users have liked this narrative

Updated Narratives

TA
Talos
NVDA logo
Talos on NVIDIA ·

Not a Bubble, But the "Industrial Revolution 4.0" Engine

Fair Value:US$294.9239.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TA
Talos
AMD logo
Talos on Advanced Micro Devices ·

The "David vs. Goliath" AI Trade – Why Second Place is Worth Billions

Fair Value:US$416.4647.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TA
Talos
PYPL logo
Talos on PayPal Holdings ·

The "Sleeping Giant" Wakes Up – Efficiency & Monetization

Fair Value:US$174.9264.2% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.6% undervalued
111 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3928.1% undervalued
945 users have followed this narrative
6 users have commented on this narrative
24 users have liked this narrative
OS
oscargarcia
GOOGL logo
oscargarcia on Alphabet ·

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

Fair Value:US$3407.4% undervalued
146 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative